- Previous Close
182.00 - Open
170.00 - Bid --
- Ask 170.00 x --
- Day's Range
170.00 - 170.00 - 52 Week Range
113.09 - 246.00 - Volume
650 - Avg. Volume
175 - Market Cap (intraday)
12.091B - Beta (5Y Monthly) 0.07
- PE Ratio (TTM)
-- - EPS (TTM)
-31.71 - Earnings Date Nov 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
altimmune.comRecent News: ALT1.MX
View MorePerformance Overview: ALT1.MX
Trailing total returns as of 12/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALT1.MX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALT1.MX
View MoreValuation Measures
Market Cap
11.35B
Enterprise Value
8.57B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.98k
Price/Book (mrq)
4.49
Enterprise Value/Revenue
8.16k
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-39.56%
Return on Equity (ttm)
-72.96%
Revenue (ttm)
52k
Net Income Avi to Common (ttm)
-103.52M
Diluted EPS (ttm)
-31.71
Balance Sheet and Cash Flow
Total Cash (mrq)
139.38M
Total Debt/Equity (mrq)
1.33%
Levered Free Cash Flow (ttm)
-45.63M